The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma

BACKGROUND: Although the bortezomib-based triple-drug therapy is considered as a front-line therapy for multiple myeloma (MM) in Chinese patients, increased level of toxicity leads to treatment dissatisfaction. Treatment with ixazomib, an oral proteasome inhibitor, has demonstrated better efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wenming, Liu, Aijun, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898406/
https://www.ncbi.nlm.nih.gov/pubmed/36463561
http://dx.doi.org/10.1007/s12325-022-02355-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898406/
https://www.ncbi.nlm.nih.gov/pubmed/36463561
http://dx.doi.org/10.1007/s12325-022-02355-3

Ejemplares similares